loratadine + pseudoephedrine




Four Star
Concise Prescribing Info
Per Repetab Loratadine 5 mg, pseudoephedrine 120 mg. Per ER tab Loratadine 10 mg, pseudoephedrine 240 mg
Relief of symptoms associated w/ allergic rhinitis & the common cold including nasal congestion, sneezing, rhinorrhea, pruritus & lacrimation.
Dosage/Direction for Use
Adult & childn ≥12 yr 1 repetab bd or 1 extended-release tab once daily.
May be taken with or without food: Swallow whole, do not chew/crush.
Hypersensitivity. Patients who are receiving irreversible MAOIs or during the 2 wk following the stopping of such treatment. Patients w/ narrow-angle glaucoma; urinary retention; CV diseases eg, ischaemic heart disease, tachyarrhythmia, severe HTN; hyperthyroidism; history of haemorrhagic stroke or w/ risk factors which could increase risk of haemorrhagic stroke.
Special Precautions
Discontinue in case of HTN, tachycardia, palpitations or cardiac arrhythmias, nausea or any other neurological sign. Patients receiving digitalis, patients w/ cardiac arrhythmias, HTN, history of MI, DM, bladder neck obstruction, positive anamnesis of bronchospasm; stenosing peptic ulcer, pyloroduodenal obstruction & obstruction of the vesical cervix. Not recommended w/ reversible MAOIs & moclobemide. Concomitant use w/ other sympathomimetics including decongestants, anorexogenics or amphetamine-type psychostimulants, antihypertensives, TCAs & other antihistamines; ergot alkaloid vasoconstrictors. Preferable to discontinue treatment 24 hr before anaesth. Discontinue at least 48 hr before skin tests. Rare hereditary problems of fructose, galactose intolerance, Lapp lactase deficiency, glucose-galactose malabsorption or sucrase isomaltase insufficiency. Should not be used in patients w/ renal or hepatic impairment; elderly >60 yr. Should not be used during pregnancy or breast-feeding. Pseudoephedrine: CNS stimulation w/ convulsions or CV collapse w/ accompanying hypotension, especially in childn, elderly, or in cases of overdose. Acute generalized exanthematous pustulosis. Increased BP, tachycardia, manifestations of CNS excitation at the recommended dose. Risk of abuse; toxicity in increased doses; tolerance; depression following rapid withdrawal. Positive doping test.
Adverse Reactions
Headache, dry mouth, somnolence, insomnia. Repetab Thirst; nervousness, depression, agitation, anorexia; dizziness; tachycardia; pharyngitis, rhinitis; constipation, nausea; fatigue.
Drug Interactions
Risk of critical HTN reactions w/ MAOIs. Reduced effect of antihypertensives. Risk of vasoconstriction & increased BP w/ bromocroptine, cabergoline, lisuride, pergolide; dihydroergotamine, ergotamine, methylergometrine; reversible & irreversible MAOIs. Risk of vasoconstriction w/ other vasoconstrictors (eg, phenylpropanolamine, phenylephrine, ephedrine, oxymetazoline, naphazoline). Increased rate of pseudoephedrine absorption w/ antacids; decreased w/ kaolin.
MIMS Class
Cough & Cold Preparations / Antihistamines & Antiallergics
ATC Classification
R01BA52 - pseudoephedrine, combinations ; Belongs to the class of systemic sympathomimetic preparations used as nasal decongestants.
Clarinase repetab
2 × 7's
Clarinase ER tab
Exclusive offer for doctors
Register for a MIMS account and receive free medical publications worth $768 a year.
Sign up for free
Already a member? Sign in